Evidence map›Paper›PMID 41646257›Full record

ArticleESMO gastrointestinal oncology2025

Preoperative metronidazole treatment to evaluate its efficacy in reducing

S De Dosso, D Christoforidis, E Merlo, A Vannelli, S Popeskou, P Gaffuri, G Lollo, L Ambrosiani, F Radaelli, M Frattini and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Evaluation ofACS infectious diseases · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

S De DossoDepartment of Medical Oncology, Oncology Institute of Southern Switzerland-EOC, Bellinzona, Switzerland.
D ChristoforidisFaculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
E MerloInstitute of Pathology EOC, Locarno, Switzerland.
A VannelliDepartment of Surgery, Ospedale Valduce, Como, Italy.
S PopeskouDepartment of Surgery, Ospedale Regionale di Lugano-EOC, Lugano, Switzerland.
P GaffuriDepartment of Surgery, Ospedale Reginale di Bellinzona e Valli-EOC, Bellinzona, Switzerland.
G LolloDepartment of Gastroenterology, Ospedale Reginale di Bellinzona e Valli-EOC, Bellinzona, Switzerland.
L AmbrosianiDepartment of Pathology, Ospedale Valduce, Como, Italy.
F RadaelliDepartment of Gastroenterology, Ospedale Valduce, Como, Italy.
M FrattiniDepartment of Laboratory of Genetics and Molecular Pathology, Istituto Cantonale di Patologia EOC, Locarno, Switzerland.
M MarengoDepartment of Surgery, Ospedale Regionale di Locarno La Carità-EOC, Locarno, Switzerland.
K GalettiDepartment of Surgery, Ospedale Beata Vergine di Mendrisio-EOC, Mendrisio, Switzerland.
G IezziFaculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) is one of the most prevalent tumour types and a leading cause of cancer-related mortality worldwide. Surgery represents the primary therapeutic option, while advanced cases are typically managed with established chemotherapy protocols, which exhibit variable response rates. Recently, the gut microbiota has been implicated in chemoresistance. Notably, Aim: This proof-of-concept trial aims to determine the effectiveness of metronidazole in reducing the Trial design: Forty patients newly diagnosed with CRC, for whom surgical resection is planned, will receive metronidazole for 10 days before surgery, which must be scheduled within 3 days following the last administration. Patients who do not receive the treatment for at least 7 days will be deemed ineligible for the study and will be replaced.

Indexed as

colon cancerFusobacterium nucleatummetronidazolemicrobiota

Identifiers

PMID41646257
PMCPMC12836538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.